modelDapsone

Diagram of Dapsone

Extends from Pharmacolibrary.Drugs.ATC.D.D10AX05.

Information

name:Dapsone
ATC code:D10AX05
route:oral
compartments:2
dosage:100mg
volume of distribution:1.12L
clearance:1.3L/h
other parameters in model implementation

Dapsone is an antibacterial sulfone drug primarily used for the treatment of leprosy (Hansen's disease), dermatitis herpetiformis, and as a prophylactic treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients. Dapsone is still approved and in use today, especially in combination therapy for leprosy and for certain skin conditions.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after a single oral 100 mg dose.

References

  1. Mirochnick, M, et al., & Spector, SA (2001). Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. Clinical pharmacology and therapeutics 70(1) 24–32. DOI:10.1067/mcp.2001.115891 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11452241

  2. Mirochnick, M, et al., & McNamara, J (1999). Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. Antimicrobial agents and chemotherapy 43(11) 2586–2591. DOI:10.1128/AAC.43.11.2586 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10543733

  3. Gatti, G, et al., & Bassetti, D (1995). Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. Antimicrobial agents and chemotherapy 39(5) 1101–1106. DOI:10.1128/AAC.39.5.1101 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7625796

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)